Ioanna Lazana

Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Gilteritinib for Prevention of Post-transplant Relapse in Patients With Acute Myeloid Leukemia and FLT3-ITD Mutation: Real-Life Data from Two Centers.

Gilteritinib for Prevention of Post-transplant Relapse in Patients With Acute Myeloid Leukemia and FLT3-ITD Mutation: Real-Life Data from Two Centers.

Journal: Transplantation and cellular therapy

Published: February 05, 2026

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.

Journal: American journal of hematology

Published: January 30, 2026

Rectal Colonization with Multidrug-Resistant Organisms and Subsequent Bloodstream Infections in Hematological Patients Undergoing Cellular Therapies.

Rectal Colonization with Multidrug-Resistant Organisms and Subsequent Bloodstream Infections in Hematological Patients Undergoing Cellular Therapies.

Journal: Transplantation and cellular therapy

Published: January 09, 2026

Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity.

Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity.

Journal: Bone marrow transplantation

Published: August 16, 2025

Use of a Foamy-Virus Vector System to Produce an 'Off-the-Shelf' Fcγ-CR-T Cell Product for the Treatment of Haematological and Solid Tumour Malignancies.

Use of a Foamy-Virus Vector System to Produce an 'Off-the-Shelf' Fcγ-CR-T Cell Product for the Treatment of Haematological and Solid Tumour Malignancies.

Journal: Immunology

Published: April 23, 2025

Donor-derived malignancy after allogeneic stem cell transplantation: a rare but well recognized complication.

Donor-derived malignancy after allogeneic stem cell transplantation: a rare but well recognized complication.

Journal: Bone marrow transplantation

Published: April 16, 2025

The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry.

The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry.

Journal: Cancers

Published: January 02, 2025

Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor.

Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor.

Journal: International journal of molecular sciences

Published: February 27, 2023

The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Journal: International journal of molecular sciences

Published: February 15, 2023

Paroxysmal nocturnal hemoglobinuria: Where are we going.

Paroxysmal nocturnal hemoglobinuria: Where are we going.

Journal: American journal of hematology

Published: January 03, 2023

Endothelial Dysfunction Syndromes after Allogeneic Stem Cell Transplantation.

Endothelial Dysfunction Syndromes after Allogeneic Stem Cell Transplantation.

Journal: Cancers

Published: December 30, 2022

Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand.

Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand.

Journal: International journal of molecular sciences

Published: December 08, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026